FIELD: biotechnology.
SUBSTANCE: multi-purpose promoter is described, which provides inside the cancer cells of gene expression of an enzyme capable to convert inside the cancer cells, but not in normal cells, the non-toxic compound - the prodrug into a toxin that contains a modified or enhanced, as compared to known promoters, set of recognition sites of proteins - transcription factors, which essential set exists in most cancer cells, but not in normal cells, and which represents a tandem combination BIRC5 and TERT promoters. Also an expression vector is described, containing multifunctional promoter. The method of killing cancer cells is proposed, leading to the synthesis of toxins inside the cancer cells.
EFFECT: invention provides new systems of transcriptional control of expression of genes-killers, that enable to create new technologies of gene therapy for cancer.
4 cl, 5 tbl, 17 ex, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIPURPOSE CANCER-SPECIFIC PROMOTERS AND USING THEM IN ANTI-CANCER THERAPY | 2013 |
|
RU2539764C2 |
| PHARMACOLOGICAL COMBINATION OF POLYCATIONIC CARRIER PEG-PEI-TAT WITH INCLUDED IN IT PLASMID CARRYING THERAPEUTIC GENES HSVtk AND GM-CSF FOR GENE THERAPY OF TUMOROUS DISEASES | 2013 |
|
RU2575077C2 |
| UNIVERSAL PROMOTER FOR EXPRESSION OF THERAPEUTIC GENES IN MAMMALIAN CELLS | 2013 |
|
RU2551784C1 |
| DRUG COMBINATION FOR GENE-IMMUNE THERAPY | 2022 |
|
RU2792683C1 |
| GENE THERAPY PREPARATION FCU1-BSFM/PP FOR TREATING SOLID TUMOURS | 2023 |
|
RU2824977C1 |
| METHODS AND COMPONENTS FOR INDUCTION OF TUMOR- -SPECIFIC CYTOTOXICITY | 1998 |
|
RU2214280C2 |
| HISTONES AND BIODEGRADABLE LIPIDES AS MEANS FOR NUCLEIC ACIDS DELIVERY TO EUKARYOTIC CELLS | 2015 |
|
RU2637371C2 |
| DETERMINATION OF TRANSFORMING ABILITY OF AGENTS | 1998 |
|
RU2214598C2 |
| PROMOTER FOR TISSUE-SPECIFIC GENE EXPRESSION IN TERMINAL MAMMAL TISSUES | 2010 |
|
RU2459870C2 |
| AGENT FOR GENE THERAPY OF MALIGNANT GROWTHS | 2010 |
|
RU2447150C1 |
